OIPE
JUN 18 2002
PATENT & TRADEMARK OFFICE
JC58

06-20-02 0430

0480/0360
1645
#7

Express Mail No.: EL 477 036 912 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Graner et al.

Application No.: 10/091,390

Filed: March 5, 2002

For: METHODS OF RECOVERING CHAPERONE PROTEINS AND COMPLEXES THEREOF

Confirmation No. 8714

Group Art Unit: 1645

Examiner: To Be Assigned

Attorney Docket No.: 8449-181-999

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BB listed on the attached revised form PTO 1449. A copy of each of the listed references is enclosed herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited."

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449 and make them of record in the file history of the above-identified application.

RECEIVED
JUL -3 2002
OIPE/JCWS

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is believed to be filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150; a duplicate of this sheet is enclosed.

Respectfully submitted,

Adriane M. Antler Reg No. 31,232
By Geraldine Lewis Bard 32,605

Date June 18, 2002

Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

OIPE
JUN 18 2002
JC58
PATENT & TRADEMARK OFFICE

Express Mail No.: EL 477 036 912 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Graner et al.

Application No.: 10/091,390

Filed: March 5, 2002

For: METHODS OF RECOVERING CHAPERONE PROTEINS AND COMPLEXES THEREOF

Confirmation No. 8714

Group Art Unit: 1645

Examiner: To Be Assigned

Attorney Docket No.: 8449-181-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or Attorneys for Applicants which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the references AA-BB listed on the attached revised form PTO 1449. A copy of each of the listed references is enclosed herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited by Applicant" instead of "List of Prior Art Cited."

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449 and make them of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this information disclosure statement is believed to be filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150; a duplicate of this sheet is enclosed.

Respectfully submitted,

Adriane M. Antler Reg No. 31,232
By Geraldine Lewis Bard 32,605

Date June 18, 2002

Adriane M. Antler (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

PATENT & TRADEMARK OFFICE JUN 18 2002 OIPE JC58

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-181-999	10/091,390
APPLICANT	CONFIRMATION NO.
Graner et al.	8714
FILING DATE	GROUP
March 5, 2002	1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,750,119	5/12/98	Srivastava			
	AB	5,837,251	11/17/98	Srivastava			
	AC	5,935,576	8/10/99	Srivastava			
	AD	5,961,979	10/5/99	Srivastava			
	AE	5,997,873	12/7/99	Srivastava			

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AF	Amato et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine" *American Society Clinical Oncology Meeting*, abstract 1278
	AG	Arnold et al., 1995, "Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96" *J. Exp. Med.* 182:885
	AH	Basu and Srivastava, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" *J. Exp. Med.* 189:797
	AI	Ciupitu et al., 1998, "Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes" *J. Exp. Med* 5: 685
	AJ	Graner et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" *Cancer Immunol. Immunother.* 49:476
	AK	Graner et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" *Clin. Can. Res.*6:909
	AL	Janetzki et al., 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" *Int. J. of Cancer* 88:232
	AM	Ishii et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96" *J. Immunol.* 162:1303
	AN	Katsanis et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" *Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer*, abstract 431
	AO	Lewis et al., 1999, "Pilot Trial of Vaccination with Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex (HSPPC-96) in Patients with Resected Pancreatic Adenocarcinoma" *American Society Clinical Oncology Meeting*, abstract 1687
	AP	Ménoret and Chandawarkar, 1998, "Heat-shock protein-based anticancer immunotherapy: an idea whose time has come" *Semin. in Oncology* 25:654

JUN 18 2002 JC58 PATENT & TRADEMARK OFFICE

	AQ	Nair et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides" *J. Immunol.* 162:6426
	AR	Nieland et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94" *PNAS* 93:6135
	AS	Peng et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" *J. Immunol. Meth.* 204:13
	AT	Srivatava et al., 1986, "Tumor rejection antigens of chemically induced sarcomas of inbred mice" *PNAS* 83:3407
	AU	Srivastava et al., 1988, "Chromosomal assignment of the gene encoding the mouse tumor rejection antigen gp9" *Immunogenetics* 28:205
	AV	Srivastava et al., 1991, "Stress-induced proteins in immune response to cancer" *Curr. Top. Microbiol. Immunol.* 167:109
	AW	Srivastava, 1993, "Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation" *Adv. Cancer Res.* 62:153
	AX	Srivastava and Udono, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy" *Curr. Opin. Immunol.* 6:728
	AY	Srivastava et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world" *Immunity* 8:657
	AZ	Tamura et al., 1997, "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations" *Science* 278:117
	BA	Yedavelli et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" *Int. J. Mol. Med.* 3:243
	BB	Ullrich et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein" *PNAS* 83:3121

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.